Influenza

Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. The best way to prevent the flu is by getting a flu vaccination each year. Every year in the United States, on average 5% to 20% of the population gets the flu; more than 200,000 people are hospitalized from flu complications, and; about 36,000 people die from flu-related causes. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.

Types of Influenza

Influenza is caused by three types of RNA viruses called influenza types A, B and C (considered different genera), which all belong to the family Orthomyxoviridae. The disease, colloquially called "flu" in humans, is generally caused by the viruses A and B, which are transmitted by aerosols from infected individuals or via close contact with infected animals.

Influenza Immunization

Influenza Epidemiology

Influenza Prognosis

Influenza Symptoms

Influenza Treatments

Influenza Pandemics

Influenza Research

Influenza Infection in Animals

Latest Influenza News and Research

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Obese or overweight patients at high risk for having worse COVID-19 outcomes

Patients who are overweight or obese have more severe COVID-19 and are highly likely to require invasive respiratory support, according to a new international study.

15 Apr 2021

UGA receives NIH contract to establish the Center for Influenza Disease and Emergence Research

The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research.

15 Apr 2021

Researchers identify two distinct phenotypes of COVID-19-associated ARDS

Approximately one in four patients hospitalized for the acute respiratory distress syndrome (ARDS) associated with severe COVID-19 infections may have a distinct phenotype (disease presentation) or biochemical profile associated with organ dysfunction, blood-clotting abnormalities and greater risk of death than patients with other, seemingly similar forms of the disease, researchers at Massachusetts General Hospital have found.

15 Apr 2021

Study observes neurological and psychiatric outcomes in recovered COVID-19 patients six months post-infection

A new study by researchers at Oxford University examines neurological and psychiatric outcomes in recovered COVID-19 patients six months post-infection.

15 Apr 2021

Future attempts to reduce Covid-19 spread should focus on tackling airborne transmission

Any future attempts to reduce the spread of covid-19 should be focused on tackling close airborne transmission of the virus which is considered to be the primary route for its circulation, according to experts in an editorial published in The BMJ.

15 Apr 2021

Allometric model shows human travel is closely related to spread of COVID-19

A new study indicates that the spread of COVID-19 is governed by power-law dynamics, suggesting that alternative modeling approaches need to be used to understand and predict its propagation.

15 Apr 2021

NIAID establishes a network of research sites to study influenza outbreaks

he National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has established a network of research sites to study the natural history, transmission and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks.

15 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

The spike protein is the main part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the infection. It consists of two subunits S1 and S2. Upon entry of the virus into the human body, the S1 subunit helps the virus bind to the angiotensin-converting enzyme 2 (ACE2) receptors on host cells.

13 Apr 2021

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers in South Africa and the UK have identified alpaca-derived nanoantibodies that potently neutralize variants of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Apr 2021

ACE2 homology in laboratory and wild animals

A new preprint research paper posted to the bioRxiv server describes the conservation of an important receptor gene for the virus among several animal species that live in close contact or proximity to humans.

13 Apr 2021

Could Zebrafish larvae be a novel animal model for SARS-CoV-2?

Researchers based in Paris, France, have explored the potential use of zebrafish larvae as animal models for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These larvae are small and cheap, so could prove a suitable medium for rapid mass testing of the disease.

13 Apr 2021

Children less likely to spread SARS-CoV-2 than adults

A study conducted by researchers in Canada suggests that children may be less likely than adults to spread the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

12 Apr 2021

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

A new study addresses an urgent need – namely, a therapeutic antibody directed specifically against a key SARS-CoV-2 antigen which is highly conserved among similar viruses, and is not easily bypassed by viral escape mutations.

12 Apr 2021

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.

12 Apr 2021

COVID19's cytokine storm ushers in a local complement storm in the lungs

A new study published in the journal Science Immunology analyzed lung epithelial cells from patients infected with COVID-19 and found the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces the complement system as a dangerous weapon for viral infection.

12 Apr 2021

Little evidence of COVID-19 vaccine nationalism in public opinion

Invariably, vaccination programs in high-income countries (HICs) are in a much better position due to their ability to secure a greater number of vaccines from multiple companies. On the contrary, lower-income countries have failed to obtain a sufficient number of vaccines.

8 Apr 2021

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

Nursing mothers who receive a COVID-19 vaccine may pass protective antibodies to their babies through breast milk for at least 80 days following vaccination, suggests new research from Washington University School of Medicine in St. Louis.

7 Apr 2021

$15.7 million NIMH grant to renew UC Davis Conte Center studying the origins of mental illness

Discovering how infections during pregnancy, such as COVID-19 and influenza, can lead to psychiatric illness and developmental disorders in offspring years later, and how to detect, prevent or treat these disorders, is the subject of a $15.7 million grant from the National Institute of Mental Health to the Conte Center at the University of California, Davis.

7 Apr 2021